Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.38
CTIC's Cash to Debt is ranked higher than
66% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. CTIC: 5.38 )
CTIC' s 10-Year Cash to Debt Range
Min: 0.07   Max: No Debt
Current: 5.38

Equity to Asset 0.48
CTIC's Equity to Asset is ranked higher than
60% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. CTIC: 0.48 )
CTIC' s 10-Year Equity to Asset Range
Min: -2.06   Max: 0.94
Current: 0.48

-2.06
0.94
F-Score: 4
Z-Score: -22.64
M-Score: 100.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -119.75
CTIC's Operating margin (%) is ranked higher than
67% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. CTIC: -119.75 )
CTIC' s 10-Year Operating margin (%) Range
Min: -123250   Max: -119.75
Current: -119.75

-123250
-119.75
Net-margin (%) -123.26
CTIC's Net-margin (%) is ranked higher than
66% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. CTIC: -123.26 )
CTIC' s 10-Year Net-margin (%) Range
Min: -169773.75   Max: -123.26
Current: -123.26

-169773.75
-123.26
ROE (%) -94.62
CTIC's ROE (%) is ranked higher than
55% of the 812 Companies
in the Global Biotechnology industry.

( Industry Median: -21.87 vs. CTIC: -94.62 )
CTIC' s 10-Year ROE (%) Range
Min: -293.4   Max: -29.18
Current: -94.62

-293.4
-29.18
ROA (%) -45.61
CTIC's ROA (%) is ranked higher than
61% of the 894 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. CTIC: -45.61 )
CTIC' s 10-Year ROA (%) Range
Min: -280.23   Max: -26.43
Current: -45.61

-280.23
-26.43
ROC (Joel Greenblatt) (%) -758.05
CTIC's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 872 Companies
in the Global Biotechnology industry.

( Industry Median: -196.35 vs. CTIC: -758.05 )
CTIC' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2377.81   Max: -38.55
Current: -758.05

-2377.81
-38.55
Revenue Growth (%) 210.70
CTIC's Revenue Growth (%) is ranked higher than
99% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -1.30 vs. CTIC: 210.70 )
CTIC' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 328.1
Current: 210.7

-100
328.1
EBITDA Growth (%) -52.90
CTIC's EBITDA Growth (%) is ranked higher than
52% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.30 vs. CTIC: -52.90 )
CTIC' s 10-Year EBITDA Growth (%) Range
Min: -84   Max: 26.1
Current: -52.9

-84
26.1
EPS Growth (%) -59.50
CTIC's EPS Growth (%) is ranked higher than
52% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.80 vs. CTIC: -59.50 )
CTIC' s 10-Year EPS Growth (%) Range
Min: -82.6   Max: 24.6
Current: -59.5

-82.6
24.6
» CTIC's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

CTIC Guru Trades in

CTIC Guru Trades in

CTIC Guru Trades in

Q4 2013

CTIC Guru Trades in Q4 2013

Jim Simons 285,747 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with CTIC



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Cell Therapeutics, Inc.

Weekly CEO Sells Highlight: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp and Dollar General Corp
According to GuruFocus Insider Data, these are the largest CEO sales during the past week: Groupon Inc., Cell Therapeutics Inc., Standard Pacific Corp. and Dollar General Corp. Read more...

Ratios

vs
industry
vs
history
P/B 9.90
CTIC's P/B is ranked lower than
61% of the 791 Companies
in the Global Biotechnology industry.

( Industry Median: 4.46 vs. CTIC: 9.90 )
CTIC' s 10-Year P/B Range
Min: 5.71   Max: 68.14
Current: 9.9

5.71
68.14
P/S 10.00
CTIC's P/S is ranked higher than
52% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 10.27 vs. CTIC: 10.00 )
CTIC' s 10-Year P/S Range
Min: 0.06   Max: 2601.04
Current: 10

0.06
2601.04
EV-to-EBIT 25.00
CTIC's EV-to-EBIT is ranked lower than
54% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. CTIC: 25.00 )
CTIC' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: 25

Valuation & Return

vs
industry
vs
history
Price/Net Cash 19.10
CTIC's Price/Net Cash is ranked lower than
67% of the 477 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. CTIC: 19.10 )
CTIC' s 10-Year Price/Net Cash Range
Min: 7.8   Max: 748.37
Current: 19.1

7.8
748.37
Price/Net Current Asset Value 16.90
CTIC's Price/Net Current Asset Value is ranked lower than
63% of the 525 Companies
in the Global Biotechnology industry.

( Industry Median: 9.60 vs. CTIC: 16.90 )
CTIC' s 10-Year Price/Net Current Asset Value Range
Min: 7.64   Max: 599.83
Current: 16.9

7.64
599.83
Price/Tangible Book 9.80
CTIC's Price/Tangible Book is ranked lower than
62% of the 736 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. CTIC: 9.80 )
CTIC' s 10-Year Price/Tangible Book Range
Min: 0.99   Max: 11.5
Current: 9.8

0.99
11.5
Price/Median PS Value 0.70
CTIC's Price/Median PS Value is ranked higher than
85% of the 725 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. CTIC: 0.70 )
CTIC' s 10-Year Price/Median PS Value Range
Min: 0.01   Max: 172.44
Current: 0.7

0.01
172.44
Forward Rate of Return (Yacktman) -648.04
CTIC's Forward Rate of Return (Yacktman) is ranked higher than
51% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. CTIC: -648.04 )
CTIC' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -648.04

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CTIC.Italy, CEPR.Germany
Cell Therapeutics, Inc. was incorporated in Washington in 1991. The Company is a biopharmaceutical company that develops, acquires and commercializes novel treatments for cancer. Its goal is to build a biopharmaceutical company with a diversified portfolio of proprietary oncology drugs. The Company's research, development, acquisition and in-licensing activities concentrate on identifying and developing new, less toxic and more ways to treat cancer. The Company is currently focusing on pixantrone, OPAXIO, and brostallicin. The Company is developing pixantrone, a novel anthracycline derivative, for the treatment of non-Hodgkin's lymphoma, or NHL, and various other hematologic malignancies, solid tumors and immunological disorders. Pixantrone was studied in its EXTEND, or PIX301, clinical trial, which is the first randomized, controlled, phase III single-agent clinical trial of pixantrone for patients with relapsed, aggressive NHL who received two or more prior therapies and who were sensitive to treatment with anthracyclines. The Company competes with pharmaceutical companies and with other specialized biotechnology companies, including Bristol-Myers Squibb Co., Sanofi-Aventis, Roche Group, Genentech, Inc., OSI Pharmaceuticals, Inc., Eli Lilly and Company, Abraxis, Neopharm Inc., Telik, Inc., TEVA Pharmaceuticals Industries Ltd. and PharmaMar. The Company is subject to federal, state and local laws, rules, regulations and policies governing the use, generation, manufacture, storage, air emission, effluent discharge, handling and disposal of certain materials, biological specimens and wastes.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide